Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
Artikel i vetenskaplig tidskrift, 2016

In 2014 the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy (RAV) conducted a review and analysis of the state of knowledge on the duration of follow-up after exposure to human immunodeficiency virus (HIV). Up until then a follow-up of 12 weeks after exposure had been recommended, but improved tests and new information on early diagnosis motivated a re-evaluation of the national recommendations by experts representing infectious diseases and microbiology, county medical officers, the RAV, the Public Health Agency, and other national authorities. Based on the current state of knowledge the Public Health Agency of Sweden and the RAV recommend, starting in April 2015, a follow-up period of 6 weeks after possible HIV-1 exposure, if HIV testing is performed using laboratory-based combination tests detecting both HIV antibody and antigen. If point-of-care rapid HIV tests are used, a follow-up period of 8 weeks is recommended, because currently available rapid tests have insufficient sensitivity for detection of HIV-1 antigen. A follow-up period of 12 weeks is recommended after a possible exposure for HIV-2, since presently used assays do not include HIV-2 antigens and only limited information is available on the development of HIV antibodies during early HIV-2 infection. If pre- or post-exposure prophylaxis is administered, the follow-up period is recommended to begin after completion of prophylaxis. Even if infection cannot be reliably excluded before the end of the recommended follow-up period, HIV testing should be performed at first contact for persons who seek such testing.

Författare

Hans Gaines

Jan Albert

Maria Axelsson

Torsten Berglund

Magnus Gisslén

Göteborgs universitet

A. Sonnerborg

Anders Blaxhult

Gordana Bogdanovic

Maria Brytting

Christina Carlander

Leo Flamholc

Per Follin

Axana Haggar

Per Hagstam

Marcus Johansson

Lars Navér

Jenny Persson Blom

Agneta Samuelson

Helena Ström

Martina Sundqvist

Veronica Svedhem Johansson

Karin Tegmark Wisell

Anders Tegnell

Rigmor Thorstensson

Infectious Diseases

2374-4235 (ISSN) 2374-4243 (eISSN)

Vol. 48 93-8

Ämneskategorier

Infektionsmedicin

DOI

10.3109/23744235.2015.1089593

PubMed

26414596